Natural Human hormone as the next antidepressant?

A search for novel treatment strategies in coping with depression has revealed that erythropoietin, or Epo, a hormone naturally produced by the kidneys to stimulate the formation of red blood cells, affects cognitive and associated neural responses in humans, and could potentially be used in the treatment of depression.

The study, published in Biological Psychiatry by Oxford University researchers based at the Department of Experimental Psychology and the Warneford Hospital, Oxford, found that Epo, known as a treatment for anaemia, modulates human brain activity associated with the processing of emotion.

Kamilla Miskowiak, a DPhil Student from the Department of Experimental Psychology, said: ‘Although depression is often related to problems in the chemistry of the brain, recent evidence also suggests that there may be structural problems as well with nerve cells not being regenerated as fast as normal, or suffering from toxic effects of stress and stress hormones.’

The researchers evaluated the effects of Epo on the neural and cognitive processing of emotional information in 23 healthy volunteers using pictures of happy and fearful faces, and functional magnetic resonance imaging (fMRI). Facial expressions of emotion provide important biological signals in human interaction. Expressions of fear may signal threat and are the most salient of our basic emotions. The researchers focused on the effects of Epo on this ‘threat relevant information.’

Results showed that Epo regulated the emotional responses of those volunteers that received it, similar to the effects of current antidepressants. A single dose of Epo reduced the cognitive and neural processing of threat relevant information in a remarkably similar way to established anti-depressant drugs, even though the test was performed seven days after administration.

The World Health Organisation has identified depression as an urgent health priority with the need for better and more effective treatment options, and Miskowiak said: ‘This finding provides support to the idea that Epo affects neurocognitive function in ways compatible with an antidepressant action and may be a candidate agent for future treatment strategies for depression.’

Source: Oxford University

Related stories:

Researchers find gene linked to severe diabetic eye and kidney diseases
Researchers at the John A. Moran Eye Center at the University of Utah and collaborative institutions have identified a gene called erythropoietin (EPO) that contributes to increased risk of severe diabetic eye and kidney diseases, called retinopathy and nephropathy.
Mice Can Sense Oxygen Through Skin
Biologists at the University of California, San Diego have discovered that the skin of mice can sense low levels of oxygen and regulate the production of erythropoietin, or EPO, the hormone that stimulates our bodies to produce red blood cells and allows us to adapt to high-altitude, low-oxygen environments.
Drug for anemic cancer patients raises risk of death
Millions of cancer patients take drugs to boost their red blood cells and health when they become anemic after chemotherapy. But a new study by Northwestern University's Feinberg School of Medicine shows these drugs, called erythropoiesis-stimulating agents (ESAs), actually raise patients' risk of death, possibly by stimulating the growth of cancer cells.
Olympic Games: Have we reached a plateau in terms of speed?
The world-record pace for the marathon continues to improve for both men and women. For men, the record pace for the marathon is now about as fast as the record pace for the 10,000-meter run just after World War II. Today, champion athletes are running more than four times farther at speeds of well under five minutes per mile.
New study examines the validity of epo testing
Recombinant human erythropoietin (rHuEpo) is a genetically engineered hormone sometimes misused by high-performance athletes such as cyclists and marathon runners to boost their endurance. The potential misuse of the drug is detected in urine collected from athletes. Since the test was introduced in 2000, 33 labs around the world have been accredited by the World Anti-Doping Agency (WADA) to administer the procedure.
Twin findings raise hopes of improved anemia treatments
A new understanding of how red blood cell production is controlled could lead to improvements in the treatment of the blood disorder anaemia, according to West Australian medical researchers.
A new way to boost red blood cell numbers
A common treatment for anemia — a deficiency in red blood cells (rbcs) caused by their insufficient production, excessive destruction, or excessive loss — is administration of recombinant erythropoietin (Epo), a hormone that stimulates the production of rbc precursors by the bone marrow.
New discovery leaves blood-doping athletes scratching their heads
A stunning discovery by German scientists may make blood doping and the treatment of severe anemia as easy as washing your hair. In the October print issue of The FASEB Journal, researchers show that the estimated 100,000 hair follicles on each person’s head have the potential to become erythropoietin (EPO) factories. EPO, the hormone primarily responsible for the creation of red blood cells, is used illegally to enhance athletic performance and is used legally to treat severe anemia associated with kidney failure and chemotherapy.

News discussion:

Medicine & Health news